Novavax (NVAX) Cash from Operations (2010 - 2026)

Novavax's Cash from Operations history runs 17 years deep, the most recent figure standing at 32400000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations rose 82.53% year-over-year to 32400000.0 in Q1 2026; TTM through Mar 2026 was 91533000.0, a 51.62% increase from a year earlier, with the FY2025 full-year figure at 244635000.0, down 180.34% from the prior year.
• Cash from Operations climbed to 32400000.0 in Q1 2026 per NVAX's latest filing, from 39475000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 314269000.0 in Q2 2024 and bottomed at 325593000.0 in Q1 2023.
• The 5-year median for Cash from Operations is 117816000.0 (2022), against an average of 87894235.29.
• Across the five-year window, Cash from Operations sank 267.86% in 2023 and surged 282.78% in 2024, its largest moves.
• Year by year, Cash from Operations stood at 117816000.0 in 2022, then slumped by 50.05% to 176781000.0 in 2023, then grew by 2.05% to 173163000.0 in 2024, then soared by 77.2% to 39475000.0 in 2025, then rose by 17.92% to 32400000.0 in 2026.
• Per Business Quant, the three latest NVAX Cash from Operations figures stand at 32400000.0 (Q1 2026), 39475000.0 (Q4 2025), and 107840000.0 (Q3 2025).